AssayIndex
BCH cross-section

BCH by compound

BCH records split by compound, with the index-wide comparison for the same compound beside each one. 23 compounds, 209 records. Cells below n=3 print their raw values instead of a median.

23 compounds209 records
CompoundClassReportsBCH median %Index median %Δ (pp)SpecPass %
TirzepatideIncretin3497.5098.55-1.0597.088
BPC-157Tissue-repair3298.7299.16-0.4498.094
SemaglutideIncretin2198.0398.89-0.8697.0100
CagrilintideIncretin1999.0598.69+0.3696.5100
CJC-1295 with DACGrowth-hormone1697.8798.95-1.0897.588
MOTS-cMetabolic1498.1699.13-0.9798.079
GonadorelinHypothalamic1498.8899.12-0.2498.586
GHRP-2Growth-hormone998.7799.28-0.5299.011
VIPTissue-repair997.4397.56-0.1397.544
AfamelanotideMelanocortin-receptor7 n=797.8699.06-1.2098.043
CJC-1295 (no DAC)Growth-hormone5 n=598.0299.09-1.0798.060
MK-677 (Ibutamoren mesylate)Non-peptide4 n=498.2399.49-1.2698.550
GHRP-6Growth-hormone4 n=498.7599.54-0.7999.025
MGFGrowth-hormone4 n=499.2299.29-0.0897.5100
AOD-9604Metabolic3 n=398.2799.29-1.0298.0100
HexarelinGrowth-hormone3 n=397.9799.59-1.6299.00
RetatrutideIncretin3 n=397.0298.37-1.3596.5100
IpamorelinGrowth-hormone2 n=2n<399.4799.050
L-Glutathione (reduced)Short2 n=2n<399.3398.50
TB-500Tissue-repair1 n=1n<399.5398.5100
PemvidutideIncretin1 n=1n<398.2596.0100
PT-141 (Bremelanotide)Melanocortin-receptor1 n=1n<399.3898.5100
SelankNeuroactive1 n=1n<399.5999.00
96.196.897.598.298.899.5100.2TirzepatideTirzepatide: Q1 97.22, median 97.50, Q3 98.07, n=34n=34BPC-157BPC-157: Q1 98.47, median 98.72, Q3 99.09, n=32outlier 97.42n=32SemaglutideSemaglutide: Q1 97.85, median 98.03, Q3 98.44, n=21outlier 99.35n=21CagrilintideCagrilintide: Q1 98.27, median 99.05, Q3 99.16, n=19n=19CJC-1295 with DACCJC-1295 with DAC: Q1 97.63, median 97.87, Q3 98.50, n=16n=16MOTS-cMOTS-c: Q1 98.02, median 98.16, Q3 98.53, n=14outlier 97.09n=14GonadorelinGonadorelin: Q1 98.72, median 98.88, Q3 99.09, n=14n=14GHRP-2GHRP-2: Q1 98.50, median 98.77, Q3 98.85, n=9n=9VIPVIP: Q1 97.39, median 97.43, Q3 97.61, n=9outlier 96.37n=9AfamelanotideAfamelanotide: Q1 97.81, median 97.86, Q3 98.11, n=7outlier 98.87n=7CJC-1295 (no DAC)CJC-1295 (no DAC): Q1 97.83, median 98.02, Q3 98.04, n=5outlier 97.41n=5MK-677 (Ibutamoren me…MK-677 (Ibutamoren me…: Q1 97.94, median 98.23, Q3 98.59, n=4n=4GHRP-6GHRP-6: Q1 98.70, median 98.75, Q3 98.87, n=4n=4MGFMGF: Q1 98.93, median 99.22, Q3 99.41, n=4n=4 Purity (% area)
Figure. Distribution per compound where n ≥ 4. Rows are ordered by coverage, not by result.

Which of these lines BCH actually stocks

Coverage here reflects what has been submitted to the index, not what is on the catalogue. Bachem Holding (Suzhou) Co., Ltd. lists considerably more than the 23 compounds above. Of those 23, 12 have been seen arriving from a domestic warehouse rather than as a cross-border consignment — that is the whole of what the index can say about which lines are held in regional stock, and it is a record of what was submitted, not a stock position. The catalogue and the current stock position are on the supplier's own site.

Browse the BCH catalogue at bachemholding.com →